Tivozanib for Recurrent Glioblastoma

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details. Identifier: NCT01846871
Recruitment Status : Completed
First Posted : May 3, 2013
Last Update Posted : December 2, 2016
National Comprehensive Cancer Network
Information provided by (Responsible Party):
Elizabeth R. Gerstner, MD, Massachusetts General Hospital

No Study Results Posted on for this Study
  Recruitment Status : Completed
  Actual Primary Completion Date : September 2014
  Actual Study Completion Date : May 2016
  Certification/Extension First Submitted : December 1, 2016